Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Cisplatin in Metastatic Triple-Negative Breast Cancer
NCT00463788Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2007
- Primary completion
- Jul 2009
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of KL-140 in triple-negative breast cancer (TNBC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Best Overall Response. Started Jun 2007; status: completed.
02
Drugs
KL-140
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00463788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00463788.